Clinical Approach to Hirsutism
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of hirsutism
Hirsutism affects approximately 5-10% of women of reproductive age worldwide, making it one of the most common endocrine complaints encountered in gynecology and primary care. It accounts for a significant proportion of referrals to endocrinology and dermatology clinics. Beyond its cosmetic impact, hirsutism often signals underlying hormonal dysfunction, with polycystic ovary syndrome (PCOS) being the most common cause, responsible for 70-80% of cases. The condition significantly affects quality of life, self-esteem, and psychological well-being, with studies showing increased rates of anxiety and depression in affected women.
Definition
Hirsutism is defined as the presence of excess terminal (coarse, pigmented) hair in women in a male-pattern distribution—areas where hair growth is androgen-dependent. This includes the upper lip, chin, chest, upper back, lower abdomen, and inner thighs. It is clinically quantified using the modified Ferriman-Gallwey score, where a score of 8 or greater (in most populations) indicates hirsutism. Importantly, hirsutism must be distinguished from hypertrichosis, which is generalized excess hair growth in non-androgen-dependent areas and is not caused by androgen excess.
Classification by Severity: The Ferriman-Gallwey Score
The modified Ferriman-Gallwey (mFG) scoring system evaluates terminal hair growth across 9 body areas, each scored from 0 (no terminal hair) to 4 (extensive terminal hair). The total score guides clinical classification.
| Severity | mFG Score | Clinical Description | Clinical Significance |
|---|---|---|---|
| Normal | Less than 8 | Minimal terminal hair in androgen-dependent areas | No further workup required unless other signs present |
| Mild Hirsutism | 8-15 | Noticeable excess hair, often limited to face and midline | Screen for polycystic ovary syndrome; consider hormonal evaluation |
| Moderate Hirsutism | 16-25 | More extensive hair growth across multiple areas | Hormonal evaluation recommended; investigate underlying cause |
| Severe Hirsutism | Greater than 25 | Extensive male-pattern hair growth | High suspicion for significant androgen excess; rule out tumor |
Population Variation
The threshold for defining hirsutism varies by ethnicity. Women of East Asian descent typically have less body hair, so a lower cutoff (mFG score of 2-3) may be appropriate. Conversely, women of Mediterranean, Middle Eastern, or South Asian descent may have higher baseline hair growth, though scores above 8-10 still warrant evaluation.
Classification by Etiology
Androgen-Dependent Hirsutism
Caused by elevated circulating androgens or increased sensitivity of hair follicles to normal androgen levels. This is the most common category and includes conditions such as polycystic ovary syndrome, non-classic congenital adrenal hyperplasia, and androgen-secreting tumors.
Idiopathic Hirsutism
Hirsutism occurring in women with regular ovulatory cycles and normal serum androgen levels. This accounts for 5-15% of cases and is thought to result from increased peripheral 5-alpha reductase activity or enhanced androgen receptor sensitivity in the hair follicle.
Classification by Onset and Progression
| Pattern | Description | Suggests |
|---|---|---|
| Peripubertal Onset, Slow Progression | Begins around menarche, worsens gradually over years | Polycystic ovary syndrome, idiopathic hirsutism, non-classic congenital adrenal hyperplasia |
| Adult Onset, Slow Progression | Develops in 20s-30s, gradual worsening | Polycystic ovary syndrome, late-onset congenital adrenal hyperplasia, obesity-related hyperandrogenism |
| Rapid Onset | Develops over weeks to months with quick progression | Androgen-secreting tumor (ovarian or adrenal), Cushing syndrome—requires urgent evaluation |
| Associated with Virilization | Hirsutism plus clitoromegaly, voice deepening, male-pattern balding | Severe hyperandrogenism—high suspicion for tumor or severe enzyme deficiency |
| Drug-Induced | Onset correlates with medication initiation | Anabolic steroids, danazol, valproic acid, phenytoin, minoxidil |
Classification by Distribution Pattern
| Distribution | Areas Involved | Clinical Implication |
|---|---|---|
| Facial Only | Upper lip, chin, sideburns | Most common presentation; may be idiopathic or early polycystic ovary syndrome |
| Central (Midline) | Chest, linea alba, periumbilical | More specific for androgen excess |
| Generalized Male Pattern | Face, chest, back, abdomen, thighs | Suggests significant hyperandrogenism; correlates with higher Ferriman-Gallwey scores |
| Generalized Non-Sexual | Arms, legs, back (non-androgen-dependent areas) | Consider hypertrichosis rather than hirsutism; different etiology |
Key Concept: The “Big Two” Causes
Polycystic ovary syndrome and idiopathic hirsutism together account for approximately 85-90% of all hirsutism cases. However, the clinical approach must always consider serious causes such as androgen-secreting tumors and Cushing syndrome, particularly when red flags are present (rapid onset, virilization, very high androgen levels).
Impact on Quality of Life
Hirsutism has profound effects beyond its physical manifestations. Studies consistently demonstrate significant psychological and social burden:
- Psychological impact: Increased rates of anxiety (up to 50%), depression (up to 30%), and reduced self-esteem
- Social functioning: Avoidance of social situations, intimate relationships, and activities requiring body exposure
- Economic burden: Significant time and cost spent on cosmetic hair removal methods
- Body image: Feelings of reduced femininity and attractiveness
These impacts underscore the importance of addressing hirsutism not merely as a cosmetic concern but as a condition warranting thorough evaluation and compassionate management.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of hirsutism
Understanding the pathophysiology of hirsutism requires knowledge of androgen physiology and hair follicle biology. The development of terminal hair in androgen-sensitive areas depends on the interplay between circulating androgens, their conversion to active forms within target tissues, and the sensitivity of hair follicle androgen receptors. Disruption at any level of this pathway can lead to hirsutism.
Androgen Production and Metabolism
| Component | Source | Function in Hirsutism |
|---|---|---|
| Testosterone | Ovaries (25%), adrenal glands (25%), peripheral conversion (50%) | Primary circulating androgen; converted to dihydrotestosterone in target tissues |
| Androstenedione | Ovaries (50%), adrenal glands (50%) | Weak androgen; serves as precursor for testosterone and estrogen |
| Dehydroepiandrosterone (DHEA) | Adrenal glands (90%), ovaries (10%) | Weak androgen; elevated in adrenal causes of hirsutism |
| DHEA-Sulfate (DHEA-S) | Adrenal glands (nearly 100%) | Exclusive adrenal marker; elevated levels suggest adrenal source |
| Dihydrotestosterone (DHT) | Peripheral conversion from testosterone by 5-alpha reductase | Most potent androgen; directly stimulates terminal hair growth |
Hair Follicle Biology and Androgen Action
Hair follicles contain androgen receptors and the enzyme 5-alpha reductase, which converts testosterone to the more potent dihydrotestosterone. The response to androgens varies by body site, explaining the characteristic distribution pattern of hirsutism.
Vellus Hair
Characteristics: Fine, short, non-pigmented
Location: Present throughout body from childhood
Androgen response: Can transform to terminal hair in androgen-sensitive areas
Terminal Hair
Characteristics: Coarse, long, pigmented
Location: Scalp, eyebrows, eyelashes (androgen-independent); beard, chest, pubic area (androgen-dependent)
Androgen response: Growth maintained or enhanced by androgens
5-Alpha Reductase
Function: Converts testosterone to dihydrotestosterone
Types: Type 1 (skin, liver) and Type 2 (hair follicle, prostate)
Clinical relevance: Increased activity causes idiopathic hirsutism; inhibitors used therapeutically
The Androgen Signaling Pathway
| Step | Process | Clinical Relevance |
|---|---|---|
| 1. Androgen Production | Ovaries and adrenals secrete testosterone, androstenedione, and DHEA | Tumors or enzyme defects at these sites cause hyperandrogenism |
| 2. Circulation and Binding | Androgens circulate bound to sex hormone-binding globulin (SHBG) and albumin; only free fraction is active | Low SHBG (in obesity, insulin resistance) increases free testosterone |
| 3. Cellular Uptake | Free testosterone enters hair follicle cells | Target for understanding tissue-specific effects |
| 4. Intracellular Conversion | 5-alpha reductase converts testosterone to dihydrotestosterone | 5-alpha reductase inhibitors (finasteride) block this step |
| 5. Receptor Binding | Dihydrotestosterone binds androgen receptor in nucleus | Androgen receptor blockers (spironolactone, flutamide) act here |
| 6. Gene Transcription | Receptor-hormone complex activates genes promoting terminal hair growth | End result: vellus to terminal hair transformation |
Sex Hormone-Binding Globulin and Insulin Resistance
The SHBG-Insulin Connection
Sex hormone-binding globulin (SHBG) is produced by the liver and binds testosterone, reducing its bioavailability. Insulin suppresses SHBG production. Therefore, in conditions with insulin resistance (obesity, polycystic ovary syndrome, type 2 diabetes), SHBG levels fall, leading to increased free testosterone and clinical hyperandrogenism—even when total testosterone may be normal.
How Conditions Cause Hirsutism
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Polycystic Ovary Syndrome | Ovarian theca cell hyperplasia leads to excess androgen production; insulin resistance reduces SHBG, increasing free testosterone | Combined oral contraceptives suppress ovarian androgens; metformin improves insulin sensitivity and raises SHBG |
| Idiopathic Hirsutism | Normal androgen levels but increased 5-alpha reductase activity or androgen receptor sensitivity in hair follicles | Peripheral androgen blockers (spironolactone) and 5-alpha reductase inhibitors most effective |
| Non-Classic Congenital Adrenal Hyperplasia | Partial 21-hydroxylase deficiency causes shunting of precursors to androgen pathway; elevated 17-hydroxyprogesterone | Low-dose glucocorticoids suppress adrenal androgen production |
| Androgen-Secreting Tumor | Autonomous production of large amounts of testosterone (ovarian) or DHEA-S (adrenal) | Surgical removal of tumor is curative |
| Cushing Syndrome | Excess cortisol and adrenal androgens; ACTH-dependent or independent | Treat underlying cause (tumor resection, medication) |
| Hyperprolactinemia | Elevated prolactin stimulates adrenal androgen production | Dopamine agonists normalize prolactin and reduce androgens |
| Obesity | Adipose tissue increases peripheral aromatization; insulin resistance lowers SHBG; often coexists with polycystic ovary syndrome | Weight loss improves insulin sensitivity, raises SHBG, reduces free androgens |
| Drug-Induced | Exogenous androgens or drugs with androgenic effects directly stimulate hair follicles | Discontinue offending medication when possible |
Distinguishing Ovarian from Adrenal Androgen Excess
Ovarian Source
Androgens elevated: Testosterone, androstenedione
DHEA-S: Normal or mildly elevated
Conditions: Polycystic ovary syndrome, ovarian hyperthecosis, ovarian tumors (Sertoli-Leydig, hilus cell)
Clinical clue: Menstrual irregularities often prominent
Adrenal Source
Androgens elevated: DHEA-S, DHEA (most specific for adrenal)
Other findings: May have elevated cortisol or 17-hydroxyprogesterone
Conditions: Non-classic congenital adrenal hyperplasia, adrenal tumors, Cushing syndrome
Clinical clue: DHEA-S greater than 700 mcg/dL suggests adrenal tumor
Often Overlooked: The Delay Between Hormones and Hair
Hair follicle cycling means there is a significant delay between hormonal changes and visible hair changes. Terminal hairs have a growth (anagen) phase lasting months to years. This explains why:
- Hirsutism may continue to worsen initially even after treatment normalizes androgens
- Response to medical therapy takes 6-12 months to become apparent
- Once terminal hairs are established, they may persist even after hormonal normalization, requiring direct hair removal methods
Metabolic and Reproductive Implications
Hirsutism often signals underlying conditions with significant metabolic and reproductive consequences beyond the cosmetic concern:
| Associated Condition | Long-Term Risks | Why It Matters |
|---|---|---|
| Polycystic Ovary Syndrome | Type 2 diabetes, cardiovascular disease, endometrial hyperplasia/cancer, infertility | Hirsutism may be the presenting complaint that leads to diagnosis of this metabolic syndrome |
| Insulin Resistance | Metabolic syndrome, fatty liver disease, increased cardiovascular risk | Often accompanies polycystic ovary syndrome; improves with weight loss and insulin sensitizers |
| Congenital Adrenal Hyperplasia | Adrenal crisis (in classic forms), infertility, short stature (if untreated in childhood) | Non-classic form often presents in adolescence/adulthood with hirsutism |
| Androgen-Secreting Tumor | Progressive virilization, metastatic disease (if malignant) | Early detection through appropriate workup prevents irreversible virilization |
3. History Taking
A comprehensive approach to eliciting the hirsutism history
Red Flags — Require Urgent Evaluation
- Rapid onset (weeks to months) — Suggests androgen-secreting tumor
- Signs of virilization — Clitoromegaly, voice deepening, male-pattern baldness indicate severe hyperandrogenism
- Pelvic or abdominal mass — Ovarian or adrenal tumor
- Cushingoid features — Central obesity, striae, buffalo hump suggest Cushing syndrome
- Galactorrhea — May indicate hyperprolactinemia or pituitary tumor
- Very high testosterone (greater than 200 ng/dL) or DHEA-S (greater than 700 mcg/dL) — Tumor until proven otherwise
Systematic History: The “HAIR-GS” Approach
Use the mnemonic “HAIR-GS” to ensure comprehensive history taking for hirsutism:
- H — Hair pattern and progression: Where is the hair? When did it start? How fast is it progressing?
- A — Associated symptoms: Acne, alopecia, menstrual irregularities, weight changes, skin changes?
- I — Impact and treatments tried: How does it affect quality of life? What hair removal or medications have been tried?
- R — Reproductive and menstrual history: Age at menarche, cycle regularity, fertility issues, pregnancies?
- G — General medical and family history: Diabetes, thyroid disease, family members with hirsutism or polycystic ovary syndrome?
- S — Substances and medications: Hormones, supplements, anabolic agents, valproic acid, other drugs?
Characterizing the Hair Growth
| Question Category | Specific Questions to Ask | Clinical Significance |
|---|---|---|
| Location | “Where exactly is the excess hair? Face, chest, abdomen, back, thighs?” | Male-pattern distribution (face, chest, midline) confirms androgen-dependent hirsutism versus hypertrichosis |
| Onset | “When did you first notice the excess hair? Around puberty or later?” | Peripubertal onset suggests polycystic ovary syndrome or congenital adrenal hyperplasia; adult onset needs broader workup |
| Progression | “Has it been gradually worsening over years, or did it appear suddenly over weeks to months?” | Rapid progression is a red flag for androgen-secreting tumor—requires urgent imaging |
| Character | “Is the hair fine and light, or coarse and dark?” | Terminal (coarse, pigmented) hair indicates androgen effect; fine hair may be hypertrichosis |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Polycystic Ovary Syndrome | Irregular periods, acne, weight gain, infertility | “Are your periods regular? Do you go months without a period? Have you had difficulty getting pregnant?” |
| Non-Classic Congenital Adrenal Hyperplasia | Early pubic hair, short stature, family history, ethnic predisposition | “Did you develop pubic or underarm hair earlier than your peers? Is there a family history of ‘hormonal problems’ or infertility?” |
| Androgen-Secreting Tumor | Rapid onset, virilization, pelvic pain or mass | “Have you noticed your voice getting deeper? Any enlargement of your clitoris? Any pelvic pain or bloating?” |
| Cushing Syndrome | Weight gain, striae, easy bruising, muscle weakness, mood changes | “Have you gained weight recently, especially around your middle? Do you bruise easily? Have you noticed purple stretch marks?” |
| Hyperprolactinemia | Galactorrhea, amenorrhea, headaches, visual changes | “Have you noticed any milky discharge from your nipples? Any headaches or changes in your vision?” |
| Thyroid Dysfunction | Weight changes, fatigue, temperature intolerance, menstrual changes | “Have you experienced unexplained weight changes, fatigue, or feeling too hot or cold?” |
| Idiopathic Hirsutism | Regular cycles, normal androgens, family history of hirsutism | “Are your periods completely regular? Do other women in your family have similar hair growth?” |
| Drug-Induced | Temporal correlation with medication | “Did the hair growth start after beginning any new medications or supplements? Are you taking any hormones, bodybuilding supplements, or steroids?” |
Menstrual and Reproductive History
Why Menstrual History is Critical
Menstrual pattern provides crucial diagnostic information:
- Regular cycles: Suggests ovulation is occurring—more likely idiopathic hirsutism or mild polycystic ovary syndrome
- Oligomenorrhea (cycles greater than 35 days): Suggests anovulation—strongly supports polycystic ovary syndrome
- Amenorrhea: May indicate polycystic ovary syndrome, hyperprolactinemia, hypothalamic dysfunction, or severe hyperandrogenism
- New amenorrhea with rapid virilization: Red flag for androgen-secreting tumor
| History Element | Questions to Ask | Significance |
|---|---|---|
| Menarche | “At what age did you get your first period?” | Early or late menarche may suggest underlying hormonal abnormality |
| Cycle Regularity | “How often do you get your period? How many days between periods?” | Cycles greater than 35 days or fewer than 9 cycles per year indicate oligomenorrhea |
| Cycle Duration | “How many days does your period last? Is bleeding heavy or light?” | Prolonged, heavy bleeding may suggest anovulatory cycles |
| Fertility | “Have you tried to become pregnant? Any difficulty conceiving?” | Infertility common in polycystic ovary syndrome due to anovulation |
| Contraception | “Are you using any hormonal contraception?” | May mask menstrual irregularities; also affects androgen levels and interpretation |
Medication and Substance History
Medications That Cause Hirsutism
- Anabolic steroids — Direct androgenic effect; common in athletes
- Testosterone (any form) — Topical, injections, pellets, even partner’s gel
- Danazol — Used for endometriosis; androgenic effects
- Valproic acid — Causes polycystic ovary syndrome-like syndrome
- Phenytoin — Causes hypertrichosis (generalized)
- Cyclosporine — Causes hypertrichosis
- Minoxidil — Causes hypertrichosis
- Glucocorticoids (high-dose) — Can cause hirsutism via adrenal axis
- Progestins with androgenic activity — Levonorgestrel, norethindrone
- DHEA supplements — Often used as “anti-aging” supplement
Important Substance History
- Over-the-counter supplements: DHEA, “testosterone boosters,” bodybuilding supplements
- Herbal products: Some contain undisclosed androgens
- Partner’s medications: Testosterone gel transfer through skin contact
- Illicit substances: Anabolic steroids, “performance enhancers”
Protective Medications to Note
- Combined oral contraceptives: Suppress ovarian androgens; may mask symptoms
- Spironolactone: Androgen blocker; already being used?
- Metformin: May indicate known polycystic ovary syndrome or insulin resistance
Family and Social History
Family History
Ask specifically about:
- Female relatives with excess hair, acne, or irregular periods (suggests familial polycystic ovary syndrome or idiopathic hirsutism)
- Diabetes or metabolic syndrome (associated with insulin resistance and polycystic ovary syndrome)
- Infertility in female relatives
- Early male-pattern baldness in male relatives (androgen sensitivity)
- Congenital adrenal hyperplasia (autosomal recessive—may have family history)
- Ethnic background (higher prevalence in Mediterranean, Middle Eastern, South Asian populations)
Social and Psychological History
Assess impact on quality of life:
- Time and money spent on hair removal
- Avoidance of social situations, intimacy, or activities
- Symptoms of anxiety or depression
- Body image concerns and self-esteem
- Impact on relationships
- Previous treatments tried and their effectiveness
- Occupation (relevant for insurance coverage or sun exposure)
Associated Symptoms to Screen For
| Symptom | Question | Suggests |
|---|---|---|
| Acne | “Do you have acne, especially severe or persistent acne?” | Hyperandrogenism (part of polycystic ovary syndrome criteria) |
| Scalp hair loss | “Have you noticed thinning hair on your scalp, especially at the crown or temples?” | Androgenetic alopecia—another sign of hyperandrogenism |
| Acanthosis nigricans | “Have you noticed darkening or thickening of the skin on your neck, armpits, or groin?” | Insulin resistance—common in polycystic ovary syndrome |
| Weight gain | “Have you had unintentional weight gain? Where do you tend to gain weight?” | Central obesity worsens insulin resistance; Cushingoid distribution if central |
| Voice changes | “Has your voice become deeper?” | Virilization—red flag for tumor |
| Increased muscle mass | “Have you noticed increased muscle bulk without training?” | Virilization—red flag for tumor |
| Libido changes | “Have you noticed changes in your sex drive?” | May increase with hyperandrogenism |
4. Physical Examination
A systematic approach for evaluating hirsutism
Systematic Framework: Use a comprehensive approach that evaluates the severity of hirsutism, searches for signs of virilization, identifies features of specific underlying conditions, and assesses metabolic comorbidities. The examination should proceed from general observation to focused assessment of androgen-sensitive areas and associated signs.
General Inspection
- Body habitus: Obesity pattern (central versus peripheral), body mass index, overall build
- Fat distribution: Central adiposity suggests insulin resistance; buffalo hump and supraclavicular fat pads suggest Cushing syndrome
- Skin: General skin quality, striae (purple striae suggest Cushing syndrome), bruising
- Voice: Deep or masculine voice indicates virilization
- Muscle bulk: Increased muscularity suggests significant androgen excess
- Affect: Signs of psychological distress, anxiety, or depression
Vital Signs and Anthropometrics
| Measurement | What to Look For | Clinical Significance |
|---|---|---|
| Blood Pressure | Hypertension | Associated with polycystic ovary syndrome, metabolic syndrome, Cushing syndrome |
| Body Mass Index | Calculate from height and weight | Obesity worsens insulin resistance and hyperandrogenism; also affects treatment choices |
| Waist Circumference | Greater than 88 cm (35 inches) in women | Central obesity indicates insulin resistance and metabolic syndrome |
| Waist-to-Hip Ratio | Greater than 0.85 | Another marker of central adiposity and cardiovascular risk |
Quantifying Hirsutism: The Modified Ferriman-Gallwey Score
How to Score
Assess terminal hair in 9 androgen-sensitive body areas. Each area is scored from 0 to 4:
- 0: No terminal hair
- 1: Minimal terminal hair
- 2: More than minimal but still limited
- 3: Considerable terminal hair
- 4: Extensive terminal hair (male-like)
Total score interpretation: Less than 8 = normal; 8-15 = mild hirsutism; 16-25 = moderate; greater than 25 = severe
| Area | What to Assess | Scoring Guide |
|---|---|---|
| Upper Lip | Terminal hair on upper lip | 1 = few at outer edges; 4 = full moustache |
| Chin | Terminal hair on chin | 1 = few scattered; 4 = full beard coverage |
| Chest | Terminal hair on chest/sternum | 1 = circumareolar; 4 = complete chest coverage |
| Upper Back | Terminal hair on upper back/shoulders | 1 = scattered; 4 = complete coverage |
| Lower Back | Terminal hair on lower back/sacrum | 1 = sacral tuft; 4 = complete coverage |
| Upper Abdomen | Terminal hair above umbilicus | 1 = few midline; 4 = complete coverage |
| Lower Abdomen | Terminal hair below umbilicus (linea alba) | 1 = few midline; 4 = inverted V pattern |
| Upper Arms | Terminal hair on upper arms | 1 = scattered; 4 = complete coverage |
| Thighs | Terminal hair on inner/anterior thighs | 1 = scattered; 4 = complete coverage |
Signs of Virilization — Red Flags
Virilization Indicates Severe Hyperandrogenism
The presence of any virilizing sign requires urgent evaluation for androgen-secreting tumor:
- Clitoromegaly: Clitoral width greater than 10 mm or length greater than 35 mm
- Voice deepening: Irreversible once established
- Male-pattern baldness: Frontal/temporal recession, vertex thinning
- Increased muscle mass: Particularly shoulders and arms
- Breast atrophy: Decrease in breast size
- Loss of female body contour: Loss of hip/waist differential
Skin Examination
| Finding | Location | Associated Condition |
|---|---|---|
| Acne | Face, chest, back | Hyperandrogenism; part of polycystic ovary syndrome criteria |
| Acanthosis nigricans | Neck (posterior), axillae, groin, under breasts | Insulin resistance—strongly associated with polycystic ovary syndrome |
| Androgenetic alopecia | Crown, frontal/temporal hairline | Hyperandrogenism; may coexist with hirsutism |
| Purple striae | Abdomen, thighs, arms (greater than 1 cm wide) | Cushing syndrome (white/silver striae are nonspecific) |
| Easy bruising | Generalized, minimal trauma | Cushing syndrome |
| Seborrhea | Scalp, face | Hyperandrogenism |
| Hyperpigmentation | Generalized or in skin folds | Adrenal insufficiency (primary) if generalized |
Head and Neck Examination
Face
- Facial plethora: Suggests Cushing syndrome
- Moon facies: Rounded face in Cushing syndrome
- Acne distribution: Hormonal acne along jawline and chin
- Facial hair pattern: Document for Ferriman-Gallwey score
Neck and Thyroid
- Acanthosis nigricans: Check posterior neck
- Thyroid: Goiter or nodules (thyroid dysfunction can affect menstruation)
- Buffalo hump: Dorsocervical fat pad in Cushing syndrome
- Supraclavicular fullness: Fat pads in Cushing syndrome
Breast Examination
- Breast development: Normal, hypoplastic, or atrophic
- Galactorrhea: Express nipples gently—milky discharge suggests hyperprolactinemia
- Periareolar hair: Include in Ferriman-Gallwey scoring (chest area)
- Breast atrophy: May indicate virilization
Abdominal Examination
- Central adiposity: Truncal obesity pattern
- Striae: Location, color (purple versus white), width
- Abdominal hair: Document for Ferriman-Gallwey score
- Masses: Palpable adrenal mass (rare—would be very large tumor)
- Hepatomegaly: May indicate fatty liver associated with metabolic syndrome
Pelvic Examination
Critical for Detecting Virilization and Ovarian Pathology
A careful pelvic examination should assess:
- External genitalia: Clitoral size (normal width less than 10 mm), labial fusion, pubic hair pattern
- Clitoromegaly: Strongly suggests severe hyperandrogenism—measure if enlarged
- Bimanual examination: Assess for ovarian enlargement or masses (though imaging is more sensitive)
- Pubic hair pattern: Male escutcheon (diamond-shaped extending to umbilicus) versus female (triangular)
Extremities
- Arm and thigh hair: Include in Ferriman-Gallwey scoring
- Muscle bulk: Increased muscularity suggests virilization
- Proximal muscle weakness: Test by having patient rise from squat—weakness suggests Cushing syndrome
- Peripheral edema: May be present with metabolic syndrome
- Acanthosis nigricans: Check axillae
Expected Findings by Etiology
| Condition | Hirsutism Pattern | Body Habitus | Other Key Findings |
|---|---|---|---|
| Polycystic Ovary Syndrome | Mild to moderate (mFG 8-20) | Often obese, central adiposity | Acne, acanthosis nigricans, normal external genitalia |
| Idiopathic Hirsutism | Mild to moderate (mFG 8-15) | Often normal BMI | No virilization, no acanthosis nigricans, normal examination |
| Non-Classic Congenital Adrenal Hyperplasia | Variable (mild to severe) | May be normal or obese | May have short stature; similar to polycystic ovary syndrome |
| Androgen-Secreting Tumor | Severe, rapidly progressive (mFG greater than 25) | Variable | Virilization (clitoromegaly, voice change, muscle bulk), possible palpable mass |
| Cushing Syndrome | Mild to moderate | Central obesity, thin extremities | Moon facies, buffalo hump, purple striae, proximal weakness, easy bruising |
| Hyperprolactinemia | Mild | Variable | Galactorrhea, visual field defects (if pituitary tumor) |
Important Teaching Point
Most patients will have unremarkable examinations beyond the hirsutism itself. In polycystic ovary syndrome and idiopathic hirsutism—which together account for approximately 85-90% of cases—the physical examination may show only excess terminal hair, with or without acne and obesity. A completely normal examination does not exclude these common diagnoses. Conversely, the presence of any virilizing sign or Cushingoid feature requires immediate further investigation.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
The differential diagnosis of hirsutism spans from common, benign conditions to rare but serious pathology. A probability-based approach ensures that common diagnoses are considered first while maintaining vigilance for red flags that suggest serious underlying disease. The clinical presentation—particularly the rate of onset, presence of virilization, and menstrual history—guides the diagnostic pathway.
Differential Diagnosis by Probability
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 70-80%) | Polycystic Ovary Syndrome | Oligomenorrhea, obesity, acne, acanthosis nigricans, infertility; onset around puberty with slow progression | None specific; diagnosis of exclusion after ruling out other causes |
| COMMON (approximately 5-15%) | Idiopathic Hirsutism | Regular menstrual cycles, normal androgen levels, family history of hirsutism; gradual onset | None; benign condition |
| LESS COMMON (approximately 1-8%) | Non-Classic Congenital Adrenal Hyperplasia (21-hydroxylase deficiency) | Similar to polycystic ovary syndrome; may have early pubarche, short stature; ethnic predisposition (Ashkenazi Jewish, Hispanic, Mediterranean) | Family history of ambiguous genitalia or salt-wasting crisis in relatives |
| LESS COMMON (approximately 1-2%) | Hyperprolactinemia | Galactorrhea, amenorrhea, headaches, visual field defects; hirsutism usually mild | Bitemporal hemianopia, severe headache (pituitary macroadenoma) |
| LESS COMMON (less than 1%) | Thyroid Dysfunction | Hypothyroidism: fatigue, weight gain, cold intolerance; Hyperthyroidism: weight loss, palpitations; menstrual irregularities in both | Severe symptoms of thyroid disease |
| LESS COMMON (less than 1%) | Cushing Syndrome | Central obesity, moon facies, buffalo hump, purple striae, proximal weakness, easy bruising, hypertension | Rapid weight gain, severe hypertension, diabetes, osteoporotic fractures |
| UNCOMMON BUT SERIOUS (less than 0.5%) | Androgen-Secreting Ovarian Tumor | Rapid onset (weeks to months), virilization, pelvic mass; types include Sertoli-Leydig cell, hilus cell, steroid cell tumors | Testosterone greater than 200 ng/dL, rapid virilization, palpable mass |
| UNCOMMON BUT SERIOUS (less than 0.5%) | Androgen-Secreting Adrenal Tumor | Rapid onset, virilization, may have Cushingoid features if cortisol co-secretion; adrenal carcinoma often large at diagnosis | DHEA-S greater than 700 mcg/dL, rapid progression, abdominal mass |
| UNCOMMON (less than 1%) | Ovarian Hyperthecosis | Severe hyperandrogenism in postmenopausal women; bilateral ovarian stromal hyperplasia; more severe than typical polycystic ovary syndrome | Virilization in postmenopausal woman |
| VARIABLE | Drug-Induced Hirsutism | Temporal relationship with medication; see drug table below | None; resolves with drug discontinuation |
Step-by-Step Approach to Hirsutism:
- Step 1: Rule out drug-induced hirsutism — Review all medications and supplements
- Step 2: Assess for red flags — Rapid onset, virilization, very high androgens suggest tumor
- Step 3: Check menstrual history — Regular cycles suggest idiopathic hirsutism; irregular cycles suggest polycystic ovary syndrome or other ovulatory dysfunction
- Step 4: Obtain baseline laboratory tests — Total testosterone, DHEA-S, and consider 17-hydroxyprogesterone
- Step 5: Apply diagnostic criteria — If criteria met, diagnose polycystic ovary syndrome; if androgens normal with regular cycles, diagnose idiopathic hirsutism
- Step 6: Pursue further testing if indicated — Based on laboratory results and clinical suspicion
Classification by Onset Pattern
| Onset Pattern | Conditions to Consider | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| Gradual Onset (Peripubertal) | Polycystic ovary syndrome, idiopathic hirsutism, non-classic congenital adrenal hyperplasia | Greater than 90% | Begins around menarche; worsens slowly over years; usually mild to moderate severity |
| Gradual Onset (Adult) | Late-onset polycystic ovary syndrome, obesity-related, drug-induced | 5-10% | Develops in 20s-40s; associated with weight gain or medication changes |
| Rapid Onset (Weeks to Months) | Androgen-secreting tumor (ovarian or adrenal), Cushing syndrome | Less than 1% | Progressive virilization; very high androgen levels; requires urgent imaging |
| Postmenopausal Onset | Ovarian hyperthecosis, ovarian tumor, adrenal tumor | Rare | New hirsutism after menopause is always concerning; rule out malignancy |
Anatomical Approach: Source of Androgen Excess
Ovarian Sources
Polycystic ovary syndrome
Ovarian hyperthecosis
Sertoli-Leydig cell tumor
Hilus cell tumor
Steroid cell tumor
Granulosa-theca cell tumor
Adrenal Sources
Non-classic congenital adrenal hyperplasia
Cushing syndrome
Adrenal adenoma
Adrenal carcinoma
ACTH-secreting tumor
Peripheral/End-Organ
Idiopathic hirsutism
Obesity (decreased SHBG)
Increased 5-alpha reductase activity
Androgen receptor hypersensitivity
Other/Mixed Sources
Drug-induced
Hyperprolactinemia
Thyroid dysfunction
Acromegaly (rare)
Drug-Induced Hirsutism and Hypertrichosis
| Drug or Drug Class | Mechanism | Pattern | Time to Resolution After Stopping |
|---|---|---|---|
| Anabolic steroids | Direct androgenic effect | True hirsutism (male pattern); may cause virilization | Months to years; some virilization may be permanent |
| Testosterone (all forms) | Direct androgenic effect | True hirsutism; dose-dependent | Months; dependent on formulation |
| Danazol | Weak androgen; suppresses SHBG | True hirsutism | 3-6 months |
| DHEA supplements | Androgen precursor | True hirsutism; usually mild | Weeks to months |
| Valproic acid | Induces polycystic ovary syndrome-like state; increases testosterone | True hirsutism with menstrual irregularity | Months after discontinuation |
| Androgenic progestins | Intrinsic androgenic activity (levonorgestrel, norgestrel, norethindrone) | True hirsutism; usually mild | Weeks to months |
| Phenytoin | Unknown; possibly altered androgen metabolism | Hypertrichosis (generalized, non-sexual pattern) | Months |
| Cyclosporine | Direct effect on hair follicle | Hypertrichosis (face, arms) | Months |
| Minoxidil | Vasodilation and direct follicle stimulation | Hypertrichosis (generalized) | 1-6 months |
| Glucocorticoids (chronic high-dose) | Adrenal suppression with relative androgen excess; Cushingoid effects | True hirsutism; facial predominant | Variable; depends on adrenal recovery |
| Diazoxide | Direct effect on hair follicle | Hypertrichosis | Months |
Polycystic Ovary Syndrome: Rotterdam Diagnostic Criteria
Diagnosis Requires 2 of 3 Criteria (After Exclusion of Other Causes)
- Oligo-ovulation or anovulation: Fewer than 9 menstrual cycles per year, or cycles greater than 35 days apart
- Clinical and/or biochemical hyperandrogenism: Hirsutism (modified Ferriman-Gallwey score 8 or greater), acne, alopecia, OR elevated testosterone/free androgen index
- Polycystic ovarian morphology on ultrasound: 12 or more follicles (2-9 mm) per ovary OR ovarian volume greater than 10 mL (note: not required if criteria 1 and 2 are met)
Important: Polycystic ovary syndrome is a diagnosis of exclusion. Other causes of hyperandrogenism and anovulation must be ruled out.
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Hirsutism + irregular periods + obesity + acanthosis nigricans | Polycystic ovary syndrome | Check testosterone, rule out other causes, apply Rotterdam criteria |
| Hirsutism + regular periods + normal androgens | Idiopathic hirsutism | Confirm normal androgens; family history often positive |
| Rapid onset + virilization + testosterone greater than 200 ng/dL | Androgen-secreting ovarian tumor | Urgent pelvic ultrasound; consider CT/MRI |
| Rapid onset + DHEA-S greater than 700 mcg/dL | Androgen-secreting adrenal tumor | Urgent adrenal CT scan |
| Hirsutism + central obesity + purple striae + proximal weakness | Cushing syndrome | 24-hour urinary free cortisol or overnight dexamethasone suppression test |
| Hirsutism + galactorrhea + amenorrhea | Hyperprolactinemia | Check prolactin level; if elevated, pituitary MRI |
| Hirsutism + elevated 17-hydroxyprogesterone | Non-classic congenital adrenal hyperplasia | ACTH stimulation test for confirmation |
| Hirsutism temporally related to new medication | Drug-induced | Discontinue offending agent if possible; reassess in 3-6 months |
| New hirsutism in postmenopausal woman | Ovarian hyperthecosis or tumor | Check testosterone and DHEA-S; imaging of ovaries and adrenals |
| Severe hirsutism + short stature + Ashkenazi/Mediterranean heritage | Non-classic congenital adrenal hyperplasia | Early morning 17-hydroxyprogesterone; ACTH stimulation test |
Distinguishing Hirsutism from Hypertrichosis
| Feature | Hirsutism | Hypertrichosis |
|---|---|---|
| Definition | Excess terminal hair in androgen-dependent (male-pattern) areas | Excess hair growth in non-androgen-dependent areas; generalized |
| Distribution | Face, chest, midline abdomen, inner thighs, lower back | Generalized (arms, legs, back) or localized; not sexual pattern |
| Androgen levels | Often elevated (except in idiopathic) | Normal |
| Menstrual history | Often irregular | Normal |
| Common causes | Polycystic ovary syndrome, idiopathic, congenital adrenal hyperplasia, tumors | Medications (phenytoin, cyclosporine, minoxidil), hypothyroidism, anorexia, porphyria, genetic |
| Treatment approach | Address underlying hormonal cause + cosmetic management | Address underlying cause or discontinue causative medication; cosmetic management |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
The investigation of hirsutism should be guided by clinical presentation. Most patients require only basic hormonal screening, while targeted testing is reserved for those with red flags or abnormal initial results. The goals are to identify the source of androgen excess, rule out serious pathology, and guide treatment decisions.
Who Needs Laboratory Investigation?
Guidelines for Testing
- All women with hirsutism should have at least basic screening (testosterone) unless hirsutism is clearly mild and cosmetic concern only
- Moderate to severe hirsutism (mFG score greater than 15): Full hormonal workup indicated
- Any menstrual irregularity: Hormonal evaluation required
- Any signs of virilization: Urgent comprehensive evaluation
- Rapid progression: Urgent evaluation with imaging
- Mild hirsutism + regular cycles + no other features: May defer testing if patient prefers cosmetic management only, but testing recommended to exclude underlying pathology
Optimal Timing for Hormonal Testing:
- Draw blood in the early morning (7-9 AM) when testosterone levels peak
- For menstruating women, test in the early follicular phase (days 1-7) of the menstrual cycle
- Discontinue hormonal contraceptives for 1-3 months before testing if possible (they suppress androgens and may mask abnormalities)
- 17-hydroxyprogesterone should ideally be drawn in the follicular phase (elevated in luteal phase physiologically)
First-Line Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Total Testosterone | Screen for hyperandrogenism | Elevated (greater than 45-60 ng/dL suggests hyperandrogenism); greater than 200 ng/dL suggests tumor | Morning sample; most sensitive single test; lab-specific reference ranges vary |
| Free Testosterone or Free Androgen Index | Assess bioavailable testosterone | May be elevated when total testosterone is normal (due to low SHBG) | Calculate free androgen index = (total testosterone × 100) / SHBG; more sensitive than total testosterone |
| DHEA-S (Dehydroepiandrosterone Sulfate) | Screen for adrenal androgen excess | Greater than 700 mcg/dL strongly suggests adrenal tumor; mild elevation in polycystic ovary syndrome and congenital adrenal hyperplasia | Exclusive adrenal marker; stable throughout day (no diurnal variation) |
| 17-Hydroxyprogesterone (17-OHP) | Screen for non-classic congenital adrenal hyperplasia | Greater than 200 ng/dL (6 nmol/L) in follicular phase warrants ACTH stimulation test | Morning, follicular phase sample; elevated in luteal phase normally |
| TSH (Thyroid Stimulating Hormone) | Rule out thyroid dysfunction | Abnormal values require further thyroid workup | Hypothyroidism can cause menstrual irregularity and mild hyperandrogenism |
| Prolactin | Rule out hyperprolactinemia | Elevated prolactin requires further evaluation (medication effect versus pituitary adenoma) | Draw fasting, avoid breast stimulation before test; mild elevation may be stress-related |
Additional First-Line Tests (Based on Clinical Context)
| Investigation | When to Order | What to Look For | Practical Points |
|---|---|---|---|
| Sex Hormone-Binding Globulin (SHBG) | Obesity, suspected insulin resistance, calculating free androgen index | Low SHBG indicates insulin resistance; increases free testosterone fraction | Low SHBG explains hirsutism with “normal” total testosterone |
| Fasting Glucose and Insulin | Suspected polycystic ovary syndrome, obesity, acanthosis nigricans | Elevated glucose (prediabetes/diabetes); high fasting insulin suggests insulin resistance | Calculate HOMA-IR if insulin resistance suspected |
| HbA1c | Screening for diabetes in polycystic ovary syndrome | 5.7-6.4% = prediabetes; 6.5% or greater = diabetes | Does not require fasting; reflects 3-month glucose control |
| Lipid Panel | Metabolic screening in polycystic ovary syndrome | Dyslipidemia (elevated triglycerides, low HDL) common in polycystic ovary syndrome | Part of cardiovascular risk assessment |
| LH and FSH | Suspected polycystic ovary syndrome, amenorrhea workup | Elevated LH:FSH ratio (greater than 2:1) supports polycystic ovary syndrome; low levels suggest hypothalamic cause | Draw in early follicular phase; less specific than previously thought |
| Pregnancy Test (beta-hCG) | Any woman of reproductive age with amenorrhea | Rule out pregnancy before further workup or treatment | Always check before initiating anti-androgen therapy (teratogenic) |
Second-Line and Targeted Investigations
If Suspecting Non-Classic Congenital Adrenal Hyperplasia
When to Suspect
- Baseline 17-OHP greater than 200 ng/dL
- High-risk ethnicity (Ashkenazi Jewish, Hispanic, Mediterranean, Slavic)
- Family history of congenital adrenal hyperplasia or ambiguous genitalia
- Early pubarche or advanced bone age in history
Confirmatory Testing
- ACTH Stimulation Test: Measure 17-OHP at baseline and 60 minutes after 250 mcg IV cosyntropin
- Diagnostic threshold: Stimulated 17-OHP greater than 1000-1500 ng/dL confirms 21-hydroxylase deficiency
- Genetic testing: CYP21A2 gene analysis for definitive diagnosis and genetic counseling
If Suspecting Androgen-Secreting Tumor
When to Suspect
- Testosterone greater than 200 ng/dL
- DHEA-S greater than 700 mcg/dL
- Rapid onset of hirsutism (weeks to months)
- Signs of virilization
- Palpable pelvic or abdominal mass
Imaging Studies
- Transvaginal Ultrasound: First-line for ovarian evaluation; can detect tumors greater than 1 cm
- Pelvic MRI: Better characterization of ovarian masses
- Adrenal CT or MRI: If DHEA-S elevated or ovarian imaging negative
- Selective venous sampling: Rarely needed; localizes occult tumors
If Suspecting Cushing Syndrome
When to Suspect
- Central obesity with thin extremities
- Purple striae (greater than 1 cm wide)
- Proximal muscle weakness
- Easy bruising, poor wound healing
- New-onset hypertension or diabetes
- Moon facies, buffalo hump
Screening Tests (Need 2 Abnormal)
- 24-hour Urinary Free Cortisol: Greater than 3 times upper limit of normal is diagnostic; collect on 2 separate days
- Overnight Dexamethasone Suppression Test: Give 1 mg dexamethasone at 11 PM, measure cortisol at 8 AM; cortisol greater than 1.8 mcg/dL is positive
- Late-Night Salivary Cortisol: Elevated on 2 occasions supports diagnosis
- If screening positive: Refer to endocrinology for confirmation and localization
If Suspecting Hyperprolactinemia
When to Suspect
- Galactorrhea
- Amenorrhea or oligomenorrhea
- Headaches or visual field changes
- Elevated prolactin on screening
Further Evaluation
- Review medications: Antipsychotics, metoclopramide, and others cause hyperprolactinemia
- Repeat prolactin: To confirm; avoid stress and breast stimulation before draw
- Pituitary MRI: If prolactin confirmed elevated and no medication cause
- Visual field testing: If macroadenoma suspected
Imaging Studies
| Imaging Modality | Indication | What It Shows | Limitations |
|---|---|---|---|
| Transvaginal Ultrasound | First-line for polycystic ovary syndrome diagnosis and ovarian mass evaluation | Polycystic ovarian morphology (12 or more follicles 2-9 mm, or volume greater than 10 mL); ovarian masses | Operator-dependent; small tumors may be missed; not needed if criteria 1 and 2 of Rotterdam met |
| Pelvic MRI | Further characterization of ovarian mass; suspected tumor with negative ultrasound | Better soft tissue characterization; can detect smaller tumors | More expensive; not first-line |
| Adrenal CT | DHEA-S greater than 700 mcg/dL; suspected adrenal tumor | Adrenal masses; adenoma versus carcinoma features | Incidentalomas common; size and imaging characteristics guide management |
| Adrenal MRI | Characterization of adrenal mass found on CT | Better differentiation of adenoma from carcinoma | Usually second-line after CT |
| Pituitary MRI | Elevated prolactin; suspected Cushing syndrome (after biochemical confirmation) | Pituitary adenoma | Incidentalomas common; correlate with biochemistry |
Laboratory Interpretation Summary
| Laboratory Pattern | Most Likely Diagnosis | Next Step |
|---|---|---|
| Testosterone mildly elevated; DHEA-S normal; irregular cycles | Polycystic ovary syndrome | Apply Rotterdam criteria; screen for metabolic comorbidities |
| All androgens normal; regular cycles | Idiopathic hirsutism | Reassurance; cosmetic management; consider trial of anti-androgen therapy |
| 17-OHP elevated (greater than 200 ng/dL) | Non-classic congenital adrenal hyperplasia | ACTH stimulation test for confirmation |
| Testosterone greater than 200 ng/dL | Androgen-secreting tumor (ovarian) | Urgent pelvic ultrasound/MRI |
| DHEA-S greater than 700 mcg/dL | Androgen-secreting tumor (adrenal) | Urgent adrenal CT |
| Testosterone and DHEA-S both elevated | Polycystic ovary syndrome, congenital adrenal hyperplasia, or mixed ovarian/adrenal source | 17-OHP to rule out congenital adrenal hyperplasia; imaging if very elevated |
| Elevated prolactin | Hyperprolactinemia | Review medications; pituitary MRI if no medication cause |
| Abnormal TSH | Thyroid dysfunction | Full thyroid panel; treat thyroid disease |
| Low SHBG with normal total testosterone | Insulin resistance-related hyperandrogenism | Calculate free androgen index; screen for metabolic syndrome |
When Empiric Treatment May Be Appropriate
Empiric Therapy Without Exhaustive Testing
In certain clinical scenarios, empiric treatment may be reasonable:
- Mild hirsutism + regular cycles + no red flags: May proceed with cosmetic management or trial of combined oral contraceptive without full workup
- Clear polycystic ovary syndrome phenotype: If Rotterdam criteria clearly met, extensive testing for rare causes may be deferred unless treatment-resistant
- Strong patient preference: Some patients prefer treatment trial over extensive testing
However, always test if: Any virilization, rapid progression, very high Ferriman-Gallwey score, or treatment failure.
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Rapid onset (weeks to months) with virilization | EMERGENT | Same-day testosterone and DHEA-S; urgent pelvic ultrasound and adrenal CT; refer to gynecologic oncology or endocrinology |
| Testosterone greater than 200 ng/dL or DHEA-S greater than 700 mcg/dL | EMERGENT | Urgent imaging to locate tumor; surgical referral |
| Cushing syndrome features (striae, proximal weakness, hypertension) | URGENT | Screening tests within 1-2 weeks; refer to endocrinology if positive |
| Moderate-severe hirsutism with menstrual irregularity | URGENT | Complete workup within 2-4 weeks; rule out serious causes before initiating treatment |
| New hirsutism in postmenopausal woman | URGENT | Hormone levels and imaging within 1-2 weeks; higher suspicion for neoplasm |
| Mild hirsutism with regular cycles, slow progression | ROUTINE | Outpatient workup; can be scheduled within weeks to months |
| Hirsutism clearly related to medication | ROUTINE | Discontinue offending agent if possible; reassess in 3-6 months |
Step 2: Classify by Severity and Presentation
Mild Hirsutism (mFG 8-15)
With regular cycles: Likely idiopathic; basic labs optional
With irregular cycles: Likely PCOS; full workup indicated
Proceed to Algorithm A
Moderate Hirsutism (mFG 16-25)
Any menstrual pattern: Full hormonal workup required
Look for: PCOS, NCAH, other causes
Proceed to Algorithm B
Severe Hirsutism (mFG >25) or Virilization
Any presentation: Urgent comprehensive evaluation
Rule out: Androgen-secreting tumor, Cushing syndrome
Proceed to Algorithm C
Step 3: Follow the Appropriate Algorithm
Algorithm A: Mild Hirsutism
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Mild hirsutism + regular cycles + no other symptoms | Idiopathic hirsutism | Optional: Check testosterone to confirm normal. Offer cosmetic management ± combined oral contraceptive or anti-androgen |
| Mild hirsutism + irregular cycles + obesity | Polycystic ovary syndrome | Check testosterone, DHEA-S, 17-OHP, TSH, prolactin. Apply Rotterdam criteria. Screen for metabolic syndrome |
| Mild hirsutism + family history of similar + regular cycles | Familial/idiopathic hirsutism | Reassurance; cosmetic management; anti-androgen therapy if desired |
| Mild hirsutism + started after new medication | Drug-induced | Discontinue or switch medication if possible; reassess in 3-6 months |
Algorithm B: Moderate Hirsutism
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Moderate hirsutism + oligomenorrhea + acne + obesity | Polycystic ovary syndrome | Full hormonal panel. Pelvic ultrasound. Metabolic screening. Initiate treatment |
| Moderate hirsutism + elevated 17-OHP (>200 ng/dL) | Non-classic congenital adrenal hyperplasia | ACTH stimulation test. If confirmed, consider low-dose glucocorticoids or combined oral contraceptive |
| Moderate hirsutism + mildly elevated DHEA-S (<700) | Adrenal hyperandrogenism (functional) | Check 17-OHP to rule out NCAH. If negative, treat as PCOS/idiopathic |
| Moderate hirsutism + elevated prolactin | Hyperprolactinemia | Review medications. If no drug cause, pituitary MRI. Treat with dopamine agonist if prolactinoma |
| Moderate hirsutism + abnormal TSH | Thyroid dysfunction contributing | Treat thyroid disease; reassess hirsutism after euthyroid |
Algorithm C: Severe Hirsutism or Virilization
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Rapid onset + virilization + testosterone >200 ng/dL | Ovarian androgen-secreting tumor | URGENT: Pelvic ultrasound → MRI if needed. Refer to gynecologic oncology. Surgical excision |
| Rapid onset + virilization + DHEA-S >700 mcg/dL | Adrenal androgen-secreting tumor | URGENT: Adrenal CT. Refer to endocrine surgery. Surgical excision |
| Severe hirsutism + central obesity + purple striae + weakness | Cushing syndrome | 24-hour urinary free cortisol AND overnight dexamethasone suppression test. Refer to endocrinology if positive |
| Postmenopausal woman + new hirsutism + elevated testosterone | Ovarian hyperthecosis or tumor | Pelvic imaging. If no mass but testosterone very high, consider bilateral oophorectomy for hyperthecosis |
| Severe hirsutism + all labs normal + rapid progression | Occult tumor (may be small) | Repeat labs. Consider MRI pelvis and adrenals. Selective venous sampling if high suspicion |
Step 4: Treatment Decision Framework
Choosing Initial Treatment
Treatment selection depends on: severity of hirsutism, desire for contraception, desire for pregnancy, presence of metabolic comorbidities, and patient preference.
| Patient Profile | First-Line Treatment | Adjunctive Options |
|---|---|---|
| Mild hirsutism, no contraception needed | Cosmetic measures (laser, electrolysis, topical eflornithine) | Add spironolactone if cosmetic measures insufficient |
| Any severity, contraception desired | Combined oral contraceptive (preferably with anti-androgenic progestin) | Add spironolactone after 6 months if inadequate response; add cosmetic measures |
| Moderate-severe hirsutism, no pregnancy desire | Combined oral contraceptive + spironolactone | Add cosmetic measures; consider finasteride if refractory |
| PCOS with metabolic syndrome | Lifestyle modification + metformin + combined oral contraceptive | Add spironolactone; cosmetic measures |
| Pregnancy desired now | Cosmetic measures only (avoid teratogenic medications) | Ovulation induction if anovulatory; treat hirsutism after pregnancy |
| Non-classic congenital adrenal hyperplasia | Low-dose glucocorticoid (dexamethasone or prednisone) OR combined oral contraceptive | Add anti-androgen if needed; genetic counseling |
| Contraindication to estrogen | Spironolactone + reliable contraception | Cosmetic measures; progestin-only options less effective for hirsutism |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient wants treatment before labs result | Can start combined oral contraceptive if no contraindications and pregnancy test negative | Review labs; adjust plan if abnormal (e.g., tumor markers elevated) |
| Patient is on hormonal contraception and wants evaluation | Can proceed with evaluation; note that androgens may be suppressed | If labs normal on contraception, either continue treatment or stop for 1-3 months and retest |
| Testosterone is borderline elevated (45-70 ng/dL) | Recheck with free testosterone or free androgen index | If free testosterone elevated, diagnosis is biochemical hyperandrogenism; treat accordingly |
| Patient refuses hormonal treatment | Emphasize cosmetic options: laser hair removal, electrolysis, topical eflornithine | Spironolactone alone (with reliable contraception) is an option |
| Hirsutism not improving after 6 months of treatment | Verify compliance; ensure adequate dose; confirm diagnosis | Add second agent (e.g., add spironolactone to combined oral contraceptive); intensify cosmetic measures |
| Patient wants to conceive | Stop all anti-androgens (teratogenic) at least 1-3 months before conception | Continue cosmetic measures; address fertility if needed (ovulation induction for PCOS) |
| Patient develops side effects from spironolactone | For irregular bleeding: can add/adjust combined oral contraceptive. For breast tenderness: often improves with time | If intolerable, switch to finasteride (with reliable contraception) or rely on combined oral contraceptive alone |
| Imaging shows adrenal incidentaloma but DHEA-S normal | Likely non-functioning incidentaloma unrelated to hirsutism | Follow adrenal incidentaloma guidelines; continue hirsutism workup for other causes |
Troubleshooting Refractory Hirsutism
Ask These Questions When Treatment Fails
- Was the treatment duration adequate? Minimum 6-12 months needed for visible improvement due to hair growth cycle
- Was patient compliance good? Verify daily medication adherence; ask about missed doses
- Were doses adequate? Spironolactone may need 100-200 mg daily; ensure therapeutic dosing
- Is the diagnosis correct? Consider retesting; rule out missed tumor or Cushing syndrome
- Are there multiple contributing causes? Patient may have PCOS plus drug-induced component
- Are cosmetic measures being used concurrently? Medical therapy prevents new terminal hairs but does not remove existing ones—direct hair removal is essential
- Has there been significant weight change? Weight gain worsens insulin resistance and hirsutism
- Is there a new medication contributing? Review all current medications
Recommended Follow-Up Schedule
| Timepoint | Assessment | Actions |
|---|---|---|
| 3 months | Tolerance of medications; side effects; early compliance check | Adjust doses if needed; address side effects; reinforce cosmetic measures |
| 6 months | First assessment of efficacy; Ferriman-Gallwey score; patient satisfaction | If inadequate response, consider adding second agent or increasing dose |
| 12 months | Full efficacy assessment; metabolic parameters if PCOS | If good response, continue current regimen; if poor response, reassess diagnosis and treatment plan |
| Annually thereafter | Ongoing monitoring; blood pressure (if on combined oral contraceptive); potassium (if on spironolactone) | Continue effective treatment; discuss long-term plans; reassess fertility goals |
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
The “Big Two” dominate: Polycystic ovary syndrome and idiopathic hirsutism account for 85-90% of all hirsutism cases. However, you must still screen for serious causes before assuming a benign diagnosis.
Rapid onset is a red flag: Hirsutism developing over weeks to months, especially with virilization, suggests an androgen-secreting tumor until proven otherwise. This requires urgent imaging.
Normal testosterone does not exclude the diagnosis: In idiopathic hirsutism, all androgens are normal. Also, total testosterone may be normal while free testosterone is elevated due to low sex hormone-binding globulin.
DHEA-S is your adrenal marker: DHEA-S greater than 700 mcg/dL strongly suggests an adrenal source (tumor or hyperplasia). It is nearly exclusively produced by the adrenal glands.
Treatment takes time: Due to the hair growth cycle, expect 6-12 months before seeing significant improvement with medical therapy. Set realistic expectations early.
Medical therapy prevents, cosmetic therapy removes: Medications reduce new terminal hair growth but do not eliminate existing terminal hairs. Patients need both medical and cosmetic approaches for optimal results.
Screen for non-classic congenital adrenal hyperplasia: Check early morning 17-hydroxyprogesterone, especially in high-risk populations (Ashkenazi Jewish, Hispanic, Mediterranean). It is underdiagnosed.
Polycystic ovary syndrome is a metabolic condition: Screen all PCOS patients for insulin resistance, prediabetes, dyslipidemia, and fatty liver. The metabolic consequences often exceed the cosmetic concerns in long-term importance.
Critical Pitfalls to Avoid
Dismissing hirsutism as “just cosmetic”: Hirsutism often signals underlying hormonal dysfunction with important metabolic and reproductive implications. Always take the symptom seriously and evaluate appropriately.
Missing the rapidly progressive case: Failure to identify rapid onset and virilization can delay diagnosis of an androgen-secreting tumor. Always ask about timeline and progression.
Forgetting drug-induced causes: Always review the medication list. Valproic acid, anabolic steroids, and even partner’s testosterone gel can cause hirsutism. This is easily missed.
Starting anti-androgens without contraception: Spironolactone, finasteride, and other anti-androgens are teratogenic. Always ensure reliable contraception before prescribing.
Expecting too-rapid improvement: Giving up on therapy before 6 months is premature. Hair cycles take time; patience and consistent treatment are essential.
Ignoring the psychological impact: Hirsutism profoundly affects quality of life, self-esteem, and mental health. Acknowledge this impact and address it compassionately.
Confusing hirsutism with hypertrichosis: Hirsutism is androgen-dependent male-pattern hair; hypertrichosis is generalized excess hair. They have different causes and treatments.
Failing to retest after stopping hormonal contraception: Oral contraceptives suppress androgens. If a patient stops them and develops worsening hirsutism, repeat the workup—previously suppressed pathology may now be apparent.
Key Takeaways
- Hirsutism is excess terminal hair in a male-pattern distribution; it affects 5-10% of women and significantly impacts quality of life.
- Polycystic ovary syndrome is the most common cause (70-80%), followed by idiopathic hirsutism (5-15%). Together, they account for the vast majority of cases.
- Red flags for serious pathology include: rapid onset, virilization (clitoromegaly, voice change, muscle bulk), testosterone greater than 200 ng/dL, and DHEA-S greater than 700 mcg/dL.
- The modified Ferriman-Gallwey score quantifies hirsutism severity: less than 8 is normal, 8-15 is mild, 16-25 is moderate, and greater than 25 is severe.
- First-line laboratory tests include total testosterone, DHEA-S, 17-hydroxyprogesterone (to screen for non-classic congenital adrenal hyperplasia), TSH, and prolactin.
- Polycystic ovary syndrome is diagnosed using Rotterdam criteria (2 of 3: oligo/anovulation, hyperandrogenism, polycystic ovaries) after excluding other causes.
- Treatment combines medical therapy (combined oral contraceptives, anti-androgens) with cosmetic measures (laser, electrolysis). Both are needed for optimal results.
- Medical treatment takes 6-12 months to show effect due to the hair growth cycle. Set realistic expectations.
- Anti-androgens (spironolactone, finasteride) are teratogenic—always ensure reliable contraception.
- Patients with polycystic ovary syndrome require metabolic screening (glucose, lipids) and long-term cardiovascular risk management.
Quick Reference Algorithm
Systematic Approach to Hirsutism:
- Assess severity: Calculate modified Ferriman-Gallwey score and document distribution
- Check for red flags: Rapid onset, virilization, very high androgens → urgent workup
- Take a focused history: Use “HAIR-GS” mnemonic; assess menstrual pattern, medications, family history
- Perform targeted examination: Document hair distribution, look for virilization, acanthosis nigricans, Cushingoid features
- Order first-line labs: Testosterone, DHEA-S, 17-hydroxyprogesterone, TSH, prolactin; consider free testosterone/SHBG
- Establish diagnosis: Apply Rotterdam criteria for PCOS; rule out NCAH, tumor, Cushing, hyperprolactinemia
- Initiate treatment: Combined oral contraceptive (if contraception desired) ± anti-androgen (with contraception) + cosmetic measures
- Follow up: Reassess at 3, 6, and 12 months; adjust treatment as needed; screen for metabolic comorbidities in PCOS